TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01100437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush
Description: Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Description: EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
Study: NCT02286947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eteplirsen
Description: Eteplirsen solution for IV infusion
Study: NCT02902952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: An eight week physical exercise intervention
Study: NCT01966783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 2 mg suppository
Description: per day
Study: NCT02902952

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: An eight week sedentary control intervention
Study: NCT03142802

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Description: In phase A of the study, patients will undergo conventional CT along with low dose CT. If patients have a normal conventional CT and a satisfactory low dose CT, they will move onto Phase B of the study in which they will undergo surveillance using low-dose CT. Three outcomes are possible with low-dose CT surveillance:~1. Normal LDCT:~   - Patient continues on the study (i.e. continued surveillance)~2. Suspicious LDCT:~   - Will undergo conventional CT and if results are normal, patient will continue on study. If conventional CT is abnormal, they will be taken off study~3. Elevated serum tumour markers or other evidence of metastatic disease:~   * Patient goes off study
Study: NCT03027700

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI scan performed on 1.5T Philips Ingenia MRI scanner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI scan performed on 1.5T Philips Ingenia MRI scanner.
Study: NCT01966783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 4 mg suppository
Description: per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine 1 g suppository
Description: per day
Study: NCT01273883

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Magnesium 532 mg a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium
Description: Magnesium 532 mg a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching form/dosage
Study: NCT01966783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 2 mg suppository/Mesalazine 1 g suppository
Description: per day
Study: NCT04375124

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma
Description: angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants
Study: NCT01273883

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching form/dosage
Study: NCT01493817

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04089722

Intervention type: DRUG
Group type: OTHER
Intervention: Deoxycholic Acid
Description: The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat.
Study: NCT02471495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synergo® RITE + MMC
Description: Synergo® system delivers homogenous microwave hyperthermia to the bladder wall in combination with bladder instillation of cold chemotherapeutic agent - Mitomycin C (MMC).The energy-delivering unit and the intravesical irrigation system are computer-controlled, The irrigation system consists of a disposable tubing line and catheter set. The catheter is a triple-lumen, silicone, transurethral Foley-type catheter.~MMC is constituted as a powder (40 mg) dissolved in 50 ml sterile water for injection.
Study: NCT02215720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study: NCT01803243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Description: Ankle foot orthoses are a common treatment method to control the foot position during walking and to prevent ankle plantar flexion contractures in cerebral palsy patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Description: Ankle foot orthoses are a common treatment method to control the foot position during walking and to prevent ankle plantar flexion contractures in cerebral palsy patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoe insole
Description: The heel of the shorter leg of the patient is lifted by a shoe insole. This procedure is commonly applied with leg length differences of up to 20mm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified shoe with sole lift
Description: The heel of the shorter leg of the patient is lifted by building up the sole of the shoe (shoe sole lift). This procedure is commonly applied with leg length differences of 20mm and more.
Study: NCT01061814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: 30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
Study: NCT01665183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Study: NCT01632566

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3031207
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin
Description: Administered orally
Study: NCT03847701

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balanced diet high in Slowly Digestible Starch
Description: The carbohydrates present in high Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Balanced diet low in Slowly Digestible Starch
Description: The carbohydrates present in low-Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
Study: NCT04342975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside + Pterostilbene
Description: It will be administered a total of 1000 mg/day of NR and 200 mg/day of Ptero in a regimen of 2 capsules of Basis™ (each capsule 250 mg of NR and 50 mg of Ptero) 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The correspondent placebo will be administered in a regimen of 2 capsules 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
Study: NCT01526161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled fluticasone propionate
Description: 100 micrograms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled fluticasone propionate
Description: 100 micrograms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol
Description: 50 m

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Double blind double dummy
Study: NCT02224859

Intervention type: DEVICE
Group type: OTHER
Intervention: HCP will place the Invictus Cranial Support Device (CSD) on the patient
Description: There is no active therapeutic treatment (e.g., medication, stimulation, etc.) associated with this device or study. All supplies for this study will be supplied by the sponsor and returned to them upon completion of the trial.~The device used in this study is a soft gel based bonnet referred to as a Cranial Support Device (CSD). In this study, after obtaining written informed consent from the patient's parent(s) or guardian(s) and confirming that the patient meets all inclusion and no exclusion criteria, the study HCP will place the CSD on the selected patient.

Intervention type: OTHER
Group type: OTHER
Intervention: human intervention
Description: This study is designed to evaluate the safety of the Invictus Cranial Support Device (CSD) when worn by medically stable infants within a neonatal intensive care unit (NICU), to evaluate the form, fit, and ease of use/application of the CSD device (i.e., utility), as well as initial impressions of safety, by health care providers (HCPs) after placing the current CSD on infants for approximately six (6) hours in a NICU
Study: NCT00456989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
Study: NCT04947891

Intervention type: PROCEDURE
Intervention: Intensive recovery management
Description: Intensive recovery management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
Study: NCT00456989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
Study: NCT01014689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene/ BPO gel with Lymecycline capsules
Description: Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adapalene/ BPO vehicle gel with Lymecycline capsules
Description: Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
Study: NCT03864653

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MoodGym
Description: MoodGym is a preexisting Internet-based CBT program that uses interactive content and character-driven narratives to help alleviate symptoms of depression and comorbid anxiety. The program also aims to improve the individual's functioning by promoting the development of skills and strategies to manage depression.~MoodGym consists of an introduction module, five structured intervention modules, and a workbook of assessments. Each MoodGym session takes place entirely on an Internet-connected tablet while in the physical co-presence of a Study Counselor, who can answer questions should they arise. Each session takes approximately one hour to complete.
Study: NCT02321436

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Subjects to receive Dysport® 500U administered intramuscularly in the targeted upper limb.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intramuscularly in the targeted upper limb.
Study: NCT03080909

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Encapsulated nutrients
Description: Amino acid + Lipid; Probiotic bacteria; Lipid; Amino acid selected on their ability to stimulate release of GLP-1 and PYY

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin, which is not expected to stimulate release of GLP-1 and PYY
Study: NCT03813537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: The experimental group will receive a phone call 3-days post procedure and asked questions based on the most frequent indications for readmission after colorectal surgery.
Study: NCT04292509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAP with stop before low
Description: cross-over comparison from stop on low to stop before low

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SAP with stop on low
Description: cross-over comparison from stop before low to stop on low
Study: NCT03707600

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil.
Study: NCT03264300

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min; conventional structural MRI; T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Advanced MRI to include: Diffusion Weighted MRI (DW-MRI) - 7 min; Chemical Exchange Saturation Transfer (CEST) - 9 min; Dynamic Susceptibility Contrast / Dynamic Contrast Enhanced MRI - 8 min; and, other advanced imaging, as needed, to be determined. Post-contrast conventional MRI to include T1-weighted anatomic MRI scan - 7 min. Repeat within 1 month.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min. Conventional structural MRI to include: T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Serial DSC-MRI: staged injections of Gd-based contrast and Ferumoxytol - 20 min. Post-contrast conventional MRI: T1-weighted anatomic MRI scan - 7 min.
Study: NCT01779024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fMRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Study: NCT02298764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard back pain treatment
Description: Standard back pain treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard back pain treatment + 10 psychotherapeutic sessions
Description: Standard back pain treatment plus 10 psychotherapeutic session, that will include the shock-trauma method somatic experiencing.
Study: NCT01928381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213 + pregabalin
Description: Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind placebo capsules to match AZD5213 and pregabalin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin capsules
Description: Double blind pregabalin capsules to match AZD5213 and placebo
Study: NCT05531175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki apply
Description: The intervention group is the group in which reiki is applied. They receives 3 sessions of hemodialysis per week.
Study: NCT02922062

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canola Oil
Description: Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be canola oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be canola oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palm Oil
Description: Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be palm oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palm Oil
Description: Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be palm oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Butter
Description: Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oils used in food preparation will be butter. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oils used in food preparation will be butter. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
Study: NCT03433014

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Levobupivacaine
Description: The infiltration group will receive local infiltration with 0.5% Levobupivacaine. The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision (2 ml for the 5-mm trocar and 3 ml for the 10-mm trocars, and 10 mL for specimen retrieval incision). The specimen retrieval incision will be performed in one of two techniques, depending on the surgeon's preference, a 4-6 cm length midline incision (extending from the Hasson trocar incision) or a 4-6 cm length Pfanensteil incision.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No infiltration
Study: NCT03829930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat is formulated for oral administration. A food effect is evident for entinostat; exposure is significantly reduced when entinostat is administered with a high fat meal. Accordingly, entinostat is to be administered on an empty stomach, at least 1 hour before and 2 hours after a meal. Entinostat tablets should not be split, crushed, or chewed. Consult the individual clinical protocols for specific dosing instructions.~Dose level 1: 3mg PO weekly. Dose level 2: 5mg PO weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Dose level 1: 160 mg PO daily. Dose level 2: 160 mg PO daily.
Study: NCT04226820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: examination: blood pressure assessment
Description: blood pressure measurement for 30 minutes, dominant side

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: examination: Flow Mediated Dilatation (FMD)-test
Description: Flow Mediated Dilatation (FMD)-test for measuring the endothelial functionality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: examination: handgrip exercise test with Near infrared spectroscopy (NIRS)-monitoring
Description: participant does a maximal exercise test by a handgrip strength test with simultaneously monitoring of the muscular oxygenation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: examination: measurement of glucose by a finger prick
Description: follow-up of blood sugar (glucose) during examinations by a finger prick
Study: NCT01851681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Study: NCT03801850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D surface scan
Description: measurement of inter fractional deformations by surface scanning
Study: NCT00605423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluocinolone Acetonide/Medidur
Description: 0.2 ug/day implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluocinolone Acetonide/Medidur
Description: 0.5 ug/day implant
Study: NCT00414102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
Study: NCT02091570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Bar
Description: Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Bar
Description: Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Bar
Description: Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence